Chrome Plugin Live! Redefine the way you read FinTwit š Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
ABOS
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
seekingalpha.com
13 hours ago
globenewswire.com
16 hours ago
globenewswire.com
16 hours ago
globenewswire.com
16 hours ago
Relative Strength
ABOS
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Quote Panel
Key Metrics
Forecast
-272%2025-EPS
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Buy
Price Target
0.00(-100.00%)
Number of analyst
0
Last analyst upgrade/downgrade
Citigroup
initialisePrevious: Not converted
2024-07-25
Now: Buy
BTIG
initialisePrevious: Not converted
2023-05-18
Now: Buy
Jefferies
initialisePrevious: Not converted
2023-05-18
Now: Hold
Scotiabank
initialisePrevious: Not converted
2023-05-18
Now: Sector Perform
Earnings Growth
YoY
Current
Estimates
Q4.22
N/A
-0.32
vsĀ -0.42
Q1.23
N/A
-0.28
vsĀ -0.23
Q2.23
N/A
-0.28
vsĀ -0.25
Q3.23
N/A
-0.24
vsĀ -0.26
Q4.23
N/A
-0.29
vsĀ -0.32
Q1.24
N/A
-0.25
vsĀ -0.28
Q2.24
N/A
-0.34
vsĀ -0.28
Q3.24
+100%
NA
vsĀ -0.24
Q4.24
N/A
-0.49
vsĀ -0.29
Q1.25
N/A
-0.49
vsĀ -0.25
Sales Growth
YoY
Current
Estimates
Q2.22
NA
NAĀ vsĀ NA
Q3.22
NA
NAĀ vsĀ NA
Q4.22
NA
NAĀ vsĀ NA
Q1.23
NA
NAĀ vsĀ NA
Q2.23
NA
NAĀ vsĀ NA
Q3.23
NA
NAĀ vsĀ NA
Q4.23
NA
290KĀ vsĀ NA
Q1.24
NA
NAĀ vsĀ NA
Q2.24
NA
NAĀ vsĀ NA
Q3.24
NA
NAĀ vsĀ NA
Return on Equity
QoQ
Q4.22
-7%
-0.07
vsĀ -0.05
Q1.23
-5%
-0.05
vsĀ -0.07
Q2.23
-7%
-0.07
vsĀ -0.05
Q3.23
-5%
-0.05
vsĀ -0.07
Q4.23
-6%
-0.06
vsĀ -0.05
Q1.24
-6%
-0.06
vsĀ -0.06
Q2.24
-8%
-0.08
vsĀ -0.06
Q3.24
-14%
-0.14
vsĀ -0.08
Institutionnal Ownership
QoQ
Q4.22
65
65
vsĀ 56
16%
Q1.23
65
65
vsĀ 65
NA
Q2.23
60
60
vsĀ 65
-8%
Q3.23
73
73
vsĀ 60
22%
Q4.23
72
72
vsĀ 73
-1%
Q1.24
84
84
vsĀ 72
17%
Q2.24
86
86
vsĀ 84
2%
Q3.24
77
77
vsĀ 86
-10%
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.
NASDAQ
Unprofitable
EPS improving
Unprofitable
EPS improving
0.04Ā ( 1.89%)
Relative Strenght
15
Volume Buzz
86%
Earning Acce
No
Dist 52w H.
58%